 |
|
Mayo researchers find race has role in incidence, survival of rare brain tumor
July 31, 2009ROCHESTER, Minn. -- The incidence of a rare and deadly tumor called primary central nervous system lymphoma (PCNSL) is two times higher in black Americans, ages 20 to 49, than in white Americans, according to a Mayo Clinic study published in the June issue of Journal of Neuro-Oncology. In patients older than 49, the results were reversed. White Americans were twice as likely as black Americans to be diagnosed with PCNSL.
PCNSL is a primary tumor of the central nervous system that may simultaneously or sequentially involve the brain, spinal cord, meninges (the covering of the brain and spinal cord) and the eyes. PCNSL most often affects the elderly, people who are immunosuppressed because of illness or transplant, and patients with AIDS. Though uncommon, this tumor is increasing in incidence, even in patients without known risk factors. About 1,500 new cases are diagnosed in the United States every year.
"We undertook this epidemiological study to look for clues about the cause of PCNSL," says Brian O'Neill, M.D., a Mayo Clinic neurologist and the senior researcher in the study. Dr. O'Neill is the director of Mayo's National Cancer Institute-designated Specialized Program of Research Excellence (SPORE) in Brain Cancer.
This study was conducted by reviewing the records of 2,665 patients between 1992 and 2002 in 13 U.S. communities that are part of the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. This program is a repository for population-based information on cancer incidence and survival, covering 26 percent of the population and balanced for geographic, race and age differences. It has been used for etiologic cancer research for more than 30 years.
In the study, researchers found the PCNSL incidence rates for adults ages 20 to 49 (all reported with a 95 percent confidence interval) were:
* Black Americans: 1.43 per 100,000 per year
* White Americans: 0.72 per 100,000 per year
Incidence rates for those older than 50 were:
* Black Americans: 0.56 per 100,000 per year
* White Americans: 1.30 per 100,000 per year
The number of American Indians, Alaska Natives and Asian/Pacific Islanders diagnosed with PCNSL was too low to draw any conclusions about disease incidence.
Patients with PCNSL typically experience a rapid decline in neurologic function, with an average duration of symptoms of only four weeks to diagnosis. Symptoms may include headaches, confusion, language disturbance, gait and balance difficulties, personality changes and an inability to concentrate. Symptoms include floaters and blurred vision when PCNSL affects the eye.
The prognosis for PCNSL is poor and appears worse for black Americans. In this study, the 12-month survival rate for white Americans was 34 percent, compared to 19 percent among black Americans. The difference between the races narrowed over time but the mortality rate continued to be better for white Americans. At the five-year mark, 16 percent of white Americans were alive, compared to only 9 percent of black Americans.
Current treatments are slowing or stopping tumor growth, sometimes dramatically, but are not increasing the cure rate. However, significant advances in the treatment of systemic lymphoma have come from critical research on new treatments. This experience has fostered increased interest in finding the cause or causative factors for PCNSL. For patients with normal immune systems, no known risk factors contribute to this brain tumor.
This is the first study to quantify incidence of PCNSL by racial groups. The study design did not allow the researchers to identify reasons for the racial differences and why they changed with age.
"We don't know if it's genetic, environmental or a combination," says Dr. O'Neill. "We don't know if the higher incidence in younger black Americans reflects socio-economic factors, access to health care, and also the role of HIV infection in black communities." However, the experience with other cancers such as multiple myeloma suggests that there may be a distinct genetic contribution. For example, the age-adjusted incidence of multiple myeloma is two times higher in black Americans than in white Americans. Another Mayo study demonstrated that the prevalence of a myeloma precursor condition in Ghanaian men was twice that in American men, supporting the hypothesis that race-related genetic susceptibility is an important issue to pursue.
Mayo Clinic
This study was conducted by reviewing the records of 2,665 patients between 1992 and 2002 in 13 U.S. communities that are part of the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. This program is a repository for population-based information on cancer incidence and survival, covering 26 percent of the population and balanced for geographic, race and age differences. It has been used for etiologic cancer research for more than 30 years.
In the study, researchers found the PCNSL incidence rates for adults ages 20 to 49 (all reported with a 95 percent confidence interval) were:
* Black Americans: 1.43 per 100,000 per year
* White Americans: 0.72 per 100,000 per year
Incidence rates for those older than 50 were:
* Black Americans: 0.56 per 100,000 per year
* White Americans: 1.30 per 100,000 per year
The number of American Indians, Alaska Natives and Asian/Pacific Islanders diagnosed with PCNSL was too low to draw any conclusions about disease incidence.
Patients with PCNSL typically experience a rapid decline in neurologic function, with an average duration of symptoms of only four weeks to diagnosis. Symptoms may include headaches, confusion, language disturbance, gait and balance difficulties, personality changes and an inability to concentrate. Symptoms include floaters and blurred vision when PCNSL affects the eye.
The prognosis for PCNSL is poor and appears worse for black Americans. In this study, the 12-month survival rate for white Americans was 34 percent, compared to 19 percent among black Americans. The difference between the races narrowed over time but the mortality rate continued to be better for white Americans. At the five-year mark, 16 percent of white Americans were alive, compared to only 9 percent of black Americans.
Current treatments are slowing or stopping tumor growth, sometimes dramatically, but are not increasing the cure rate. However, significant advances in the treatment of systemic lymphoma have come from critical research on new treatments. This experience has fostered increased interest in finding the cause or causative factors for PCNSL. For patients with normal immune systems, no known risk factors contribute to this brain tumor.
This is the first study to quantify incidence of PCNSL by racial groups. The study design did not allow the researchers to identify reasons for the racial differences and why they changed with age.
"We don't know if it's genetic, environmental or a combination," says Dr. O'Neill. "We don't know if the higher incidence in younger black Americans reflects socio-economic factors, access to health care, and also the role of HIV infection in black communities." However, the experience with other cancers such as multiple myeloma suggests that there may be a distinct genetic contribution. For example, the age-adjusted incidence of multiple myeloma is two times higher in black Americans than in white Americans. Another Mayo study demonstrated that the prevalence of a myeloma precursor condition in Ghanaian men was twice that in American men, supporting the hypothesis that race-related genetic susceptibility is an important issue to pursue.
Mayo Clinic
Brain Tumor Current Events and Brain Tumor News RSSBarrow study identifies new way to biopsy brain tumors in real time
A new miniature, hand-held microscope may allow more precise removal of brain tumors and an easier recognition of tumor locations during surgery.
Men leave: Separation and divorce far more common when the wife is the patient
A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact.
Childhood cancer survivors less likely to marry, Yale researchers find
Adult survivors of childhood cancer are 20 to 25 percent more likely to never marry compared with siblings and the general population, Yale School of Medicine researchers report in a new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Brain tumors in childhood leave a lasting mark on cognition, life status
Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.
Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
Researchers report benefits of new standard treatment study for rare pediatric brain cancer
A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor.
Unequal access: Hispanic children rarely get top-notch care for brain tumors
Hispanic children diagnosed with brain tumors get high-quality treatment at hospitals that specialize in neurosurgery far less often than other children with the same condition, potentially compromising their immediate prognosis and long-term survival, according to research from Johns Hopkins published in October's Pediatrics.
tudy: The new buzz on detecting tinnitus
It's a ringing, a buzzing, a hissing or a clicking - and the patient is the only one who can hear it. Complicating matters, physicians can rarely pinpoint the source of tinnitus, a chronic ringing of the head or ears that can be as quiet as a whisper or as loud as a jackhammer.
New Approach for the Treatment of Malignant Brain Tumors
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence.
Weizmann Institute Scientists Discover A New Protein Partnership That Leads to Pediatric Tumor Regression
Why are some pediatric cancers able to spontaneously regress? Prof. Michael Fainzilber and his team of the Weizmann Institute's Biological Chemistry Department seem to have unexpectedly found part of the answer.
More Brain Tumor Current Events and Brain Tumor News Articles
 |
Curveball: When Life Throws You a Brain Tumor by Liz Holzemer (Author) Life seemed idyllic for thirty-two-year-old Liz Holzemer. Wife of Major League Baseball pitcher Mark Holzemer, Liz was enjoying a successful career as a journalist when an MRI revealed a baseball-size brain tumor she soon found out was called meningioma. Told with clarity and unwavering humor, this book is an inspirational and informative account of one woman’s battle for her life. It shows how she emerged from this frightening diagnosis and two brain surgeries retaining her remarkable spirit of survival and renewed sense of purpose and hope. With practical information about meningioma and brain surgery, Curveball is a manual for people who face life-altering challenges and is also proof that one need not fight such battles alone. |
 |
Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black (Author) Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors. This invaluable resource tells patients everything they need to know to understand and address their diagnosis, in a four-part structure: • “What is a Brain Tumor?" provides straightforward information about how brain tumors are diagnosed, the different types of tumors and how they develop, and where to go for treatment. • “Coping with Shock” addresses the emotional... |
 |
Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by Harry Wolf (Author) June 3, 2002 was the day that changed my life forever. A 43-year-old father of three, whom in oneday went from being a successful senior manager to a man with a braintumor. I have a glioblastoma multiformegrade IV brain tumor, the most deadly and aggressive type of brain tumor. This book covers how I have dealt with lifeafter being informed that I have a tumor that only 1-2% survive for 2years. I share the experiences, thoughts,and events from my first year as a survivor. When I was first diagnosed, I searched for a book that covered thedetails of what could be expected on both a medical and personal level. I could not find, so I wrote one. I maintained a detailed journal. I cover the first surgery, an awakecraniotomy, and the subsequent head infection that led to a second... |
 |
Guerilla Guide to Brain Tumors: Shameless Dirty Tricks to beat the system and STAY ALIVE! by Skip Goebel (Author) In an unprecedented format, the Guerilla Guide to Brain Tumors is written in a format that combines the layout of the For Dummies series with a drill-sargent's attitude. (the back page says it all) This is a book of War Nothing warm and fuzzy or socially acceptable here and nothing about "Dying with Dignity". Just what it takes to win. And win you will, complete with a trail of wreckage behind you. It's a book for the patient, NOT the caregiver. The Guerilla Guide to Brain Tumors is a book that will take you out of the "Grovel and Wretch" mode and into the "Command and Dominate" mode with the following factions of our society: The Medical EstablishmentThe Social Services EstablishmentChurch, Friends and FamilyAnd most importantly...Yourself No punches are pulled here. Prepare to be... |
 |
Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer (Author) A guidebook for the 150,000+ people/ year and families affected by brain tumors. This book will help you learn the basics about diagnosis, getting organized and finding your medical team. Included are chapters on all major types of brain tumors & metastases, glossary, medications, using the Internet to search for information, and getting a second opinion. "Brain Tumors:Leaving the Garden of Eden" is all about improving your odds by gathering information, & assessing your situation: What you need to do; what you need to know; what you can do now! |
 |
Searching for Normal, My Life with a Brain Tumor by Mikki Baker (Author) This is a simple and true story of a young nurse, wife and mother of three, leading a typical American middle-class life, until one day in April 2003. It is a deeply personal and detailed account from Mikki Baker, of how a grand mal seizure on Easter Monday led to the discovery of a large brain tumor, and sent her life and the lives of her family into initial chaos, and how it forever changed the course of the daily existence. The story follows the events from the day of the seizure through the first four-and-a-half years of recovery following the surgery, with the day-to-day details drawn from a journal started by family members. It is a reflection of many of the procedures, problems and emotions that brain tumor patients encounter. The reader will see how very gradual the recovery... |
 |
Brain Surgeon: A Doctor's Inspiring Encounters with Mortality and Miracles by Keith Black (Author), Arnold Mann (Author) Welcome to tiger country: the treacherous territory where a single wrong move by a brain surgeon can devastate-or end-a patient's life. This is the terrain world-renowned neurosurgeon Keith Black, MD, enters every day to produce virtual medical miracles. Now, in BRAIN SURGEON, Dr. Black invites readers to shadow his breathtaking journeys into the brain as he battles some of the deadliest and most feared tumors known to medical science. Along the way, he shares his unique insights about the inner workings of the brain, his unwavering optimism for the future of medicine, and the extraordinary stories of his patients-from ministers and rock stars to wealthy entrepreneurs and uninsured students-whom he celebrates as the real heroes. BRAIN SURGEON offers a window into one man's... |
 |
100 Q&A About Brain Tumors (100 Questions & Answers) by Virginia Stark-Vance (Author) Consumer text provides authoritative, practical answers to questions regarding treatment options, post-treatment quality of life, and sources of support. Co-authored by a brain-tumor survivor, text explains what to expect after the diagnosis and the treatment of a brain tumor. Softcover. |
 |
Brain Tumors (Diseases and Disorders) by Arda Darakjian Clark (Author) Brain tumors, both benign and malignant, present severe challenges to patients, their families, and to the medical professionals who treat them. This book discusses symptoms and diagnosis of brain tumors, standard and experimental treatments, and the need for care and rehabilitation following treatment. (20051001) |
 |
Brain Tumors: Finding the Ark. Meeting the Challenges of Treatment Choices, Side Effects, Childrens Issues, Healthcare Costs and Long Term adjustment by Paul M. Zeltzer (Author) In this sequel to Brain Tumors: Leaving the Garden of Eden, Dr. Paul continues to guide you through the brain tumor minefield so you have the best chances for quality survival. Here are the key answers to questions about medications, side effects and late effects of treatment, insurance, Medicare & HMOs, clinical trials, heredity, brain tumors in children, Complementary and Alternative Medicines & Lists of 250 major brain tumor treatment centers worldwide (30 blk-and-white illustrations , 350 websites and other resources to contact.) |
| © 2009 BrightSurf.com |